Simultaneous Determination of Co-formulated Matrine and Secnidazole in Suppositories by Reverse Phase High Performance Liquid Chromatography

Haixia Lv, Suying Ma,*, Xiao Wang and Xiaojun Shang
School of Pharmacy, Xinxiang Medical University, Xinxiang Henan, 453003, PR China

*For correspondence: Email: suyingma@163.com; Tel: + 86-373-3029879

Received: 20 February 2012 Revised accepted: 28 March 2013

Abstract

Purpose: To develop and validate a new, simple, sensitive and accurate high performance liquid chromatographic (HPLC) method for the simultaneous determination of matrine and secnidazole in suppositories.

Methods: The method involved using a SinoChoom ODS-BP C18 column (5 µm, 4.6 mm × 200 mm) and mobile phase consisting of acetonitrile–triethylamine (0.05 %) in 0.025 mol/L KH2PO4 (20:80, v/v). The flow rate was 1 mL/min and detection was monitored at 210 and 311 nm for matrine and secnidazole, respectively. Total run time was 10 min and the column was maintained at 35 °C.

Results: The excipients in the suppository did not interfere with the drug peaks. Matrine was eluted at a retention time (RT) of 4.30 min while linearity for the quantification of drug was obtained in the concentration range of 10.0 - 100.0 µg/mL ($r^2 = 0.9991$). Secnidazole was eluted at a retention time (tr) of 6.69 min and linearity for the quantification of the drug was obtained in the concentration range of 10.0 - 150.0 µg/mL ($r^2 = 0.9993$). Intra- and inter-day variations were < 1.0 % for both matrine and secnidazole.

Conclusion: The developed HPLC method was validated according to International Conference on Harmonisation (ICH) guidelines and proved to be suitable for the simultaneous determination of matrine and secnidazole in suppositories.

Keywords: Matrine, Secnidazole, Suppository, HPLC, Assay

INTRODUCTION

Bacterial vaginosis is a common cause of malodorous vaginal discharge in women of reproductive age, occurring in up to 30 % of women [1]. Besides being unpleasant for patients when symptoms of discharge and odour occur, bacterial vaginosis is associated with increased risk of several pathological gynaecological conditions as well as major adverse outcomes during pregnancy. It is estimated that bacterial vaginosis is associated with a two-fold increased risk of pre-term birth and a six-fold increased risk of miscarriage [2]. Bacterial vaginosis is also associated with increased susceptibility to sexually transmitted infections, including herpes simplex viruses, human papillomavirus, and human immunodeficiency virus[3,4].

Secnidazole, chemically 1-(2-hydroxypropyl)-2-methyl-5-nitroimidazole (Fig.1), is a new second generation 5-nitroimidazole product [5]. It is a nitroimidazole antibiotic with a broad spectrum of
activity against anaerobic microorganisms, higher efficacy, fewer adverse effects and has a longer half-life than metronidazole. It was widely used for the treatment and prevention of certain bacterial and protozoal diseases clinically. Used as a single-dose oral regimen, it appears effective in the treatment of amebiasis, giardiasis, trichomoniasis, and bacterial vaginosis.\[6,7\]

Matrine, chemically \(\text{7aS,13aR,13bR,13cS)-dodecahydro-1H,5H,10H-}
\(\text{dipyrido}[2,1-f:3',2',1'-'ij]}\) naphthyridin-10-one (Fig. 1), is an important ingredient extracted from Sophora flavescens Ait, Sophora subprostrata, and Sophora alopecuroides L., which are leguminous plants widely distributed in the northwestern region of China and are important Chinese herbal remedies. It has been proved that matrine is a nitrogen-containing heterocyclic, which belong to the quinolizidine alkaloids. It is very soluble in water, chloroform and benzene \[8-12\]. It has a wide range of pharmacological applications including anti-inflammatory, antendotoxic and anticancer with no obvious toxicity or side effect \[13\]. The suppository combining matrine and secnidazole can play synergistic roles for effective treatment of gynecological diseases.

EXPERIMENTAL

Materials

Pure matrine and secnidazole used as working standards were received as gifts from Zhongzhou Pharmaceuticals Co., Ltd, (Zhengzhou, PR China). Acetonitrile of HPLC grade and other chemicals of AR grade were purchased from Mingshen Chemicals Co, Ltd, (Zhengzhou, PR China). Deionized water was obtained using a Milli-Q water purification system (Millipore, Bedford, MA, USA). All other chemicals were used as received without further purification.

Preparation of matrine/secnidazole suppositories

Matrine/secnidazole suppositories were prepared by fusion method. Mixtures of gelatin, glycerin and water (10:15:15, w/v) were used as suppository bases; the mixture was placed in a beaker and melted by heating to 70 °C in a hot water bath. Secnidazole (16 g) and matrine (4 g) were mixed with the molten base, poured into a 10 holes steel suppository mold and allowed to solidify at room temperature. After solidification, the formed suppositories were removed from the mold, wrapped with aluminum foil, and stored in a desiccator with silicone in the refrigerator at 4 °C pending further use. Each of the suppositories was formulated to contain 200 mg secnidazole and 50 mg matrine.

Determination of matrine and secnidazole

Chromatographic analysis was performed using a Shimadzu system that comprised of LC-20AT pump, SPD 20A UV-visible absorbance detector connected to Shimadzu Spin Chrome software. ODS-BP C\(_{18}\) column (5 μm, 4.6 mm×200 mm) was used and the sample injection was performed via a Rheodyne syringe.

The mobile phase was a mixture of acetonitrile-triethylamine (0.05 %) in 0.025 mol/L KH\(_2\)PO\(_4\) (20:80, v/v). The flow rate was 1.0 mL/min. The mobile phase was degassed by an ultrasonic bath and filtered through a 0.45μm membrane filter under vacuum. The eluents were detected and quantified at 210 nm from 0 min to 5.5 min and at 311nm from 5.5 min to 10.0 min. The column was maintained at 35 °C and injection volume was 20 µL.
Preparation of standard stock solutions and working solutions

The standard solutions of the pure drugs were prepared by dissolving accurately 100 mg matrine and 150 mg secnidazole in separate 10 mL volumetric flasks using the mobile phase, respectively. The volumes were made up to the mark with mobile phase. Intermediate and working solutions were prepared by diluting stock solutions with the mobile phase. Calibration standard solutions were prepared in the concentration range of 10 to 100 µg/mL for matrine and 10 to 150 µg/mL for secnidazole, and injected into the system in triplicate. The chromatogram peak area of each drug concentration was calculated. The regression of the drug concentration versus the peak area was obtained.

Quantification of matrine and secnidazole in suppository

Ten suppositories were accurately weighed and crushed to fine particles in a mortar and an amount equivalent to one suppository was transferred into a 100 mL volumetric flask. The mixture was dissolved and then made up to volume with mobile phase. It was kept in an ultrasonic bath for 5 min and the solution filtered through a 0.45 µm filter paper. Suitable aliquots of the filtered solution were transferred to a volumetric flask and made up to volume with mobile phase to yield concentrations of matrine (20.0 µg/mL) and secnidazole (80.0 µg/mL). A 20 µL aliquot of the sample solution was injected into the chromatographic system three times under optimized chromatographic conditions. The peak area was measured at 210 nm from 0 to 5.5 min and at 311 nm from 5.5 to 10.0 min for matrine and secnidazole, respectively. Drug concentrations of the samples were determined by interpolation from calibration plots of each drug previously obtained.

Method validation

The method was validated with parameters of specificity, linearity, accuracy, precision, reproducibility and robustness.

Specificity

Combined working solution (matrine 20.0µg/mL, secnidazole 80.0µg/mL), blank excipients sample without matrine and secnidazole, equal concentrations sample of combined suppository (matrine 20.0µg/mL, secnidazole 80.0µg/mL) made with above procedure were scanned from 200nm to 400nm, and then the chromatograms were recorded.
were 4.30 and 6.69 min, respectively. Analyte peaks were well resolved and free from tailing (<1.5 for both analytes). The excipients in the suppository did not interfere with the detection of matrine and secnidazole.

**Figure 2:** Chromatograms of (a) matrine (RT = 4.30) and secnidazole (RT = 6.69); (b) blank gelatin and glycerin excipients sample, and (c) suppository sample

**Linearity**

Under optimal conditions, the calibration curve obtained by plotting peak area against concentration showed linearity in the concentration range of 10.0 - 100.0 µg/mL for matrine and 10.0 - 150.0 µg/mL for secnidazole. The regression equations, \( y = 28.266x + 25.017 \) for matrine and \( y = 43.774x - 12.475 \) for secnidazole were established based on the standard samples injected, with correlation coefficients of 0.9991 and 0.9993 respectively; where \( y \) is peak area based on three parallel measurements and \( x \) is the concentration (µg/ml) of matrine or secnidazole standard solution. The correlation coefficients indicate a good linear relationship between peak area and concentration over a wide range.

**Accuracy**

Mean recovery for matrine and secnidazole was 99.88 and 100.13 %, respectively.

**Precision**

The measurements of intra- and inter-day variability were utilized to determine the precision of the developed method. The relative standard deviation (RSD) of intra-day variation for matrine was 0.75 % and for inter-day variation 0.81% while the corresponding values for secnidazole were 0.69 and 0.72 %. The low values of RSD indicate that the method was precise. Injection repeatability values of matrine and secnidazole were 0.87 and 0.64 %, respectively. Reproducibility was checked by having the samples analyzed by another analyst using same instrument and same laboratory. There was no significant difference between the RSD values, which indicate that the proposed method was reproducible.

**Robustness**

The robustness test results for the developed method are as shown in Table 1. It is clear that there was no significant change in peak area and retention time of matrine and secnidazole when the ratio of acetonitrile, flow rate and column temperature were varied (\( p < 0.05 \)). The results indicate that the developed method was sufficiently robust for normally expected variations in chromatographic conditions.

**Content of matrine and secnidazole in suppositories**

Matrine and secnidazole, when co-formulated in suppositories, were simultaneously determined with the proposed method. The results of the assay yielded 100.07 ± 0.45 % for matrine and 99.92 ± 0.38 % for secnidazole, thus showing that the method was selective and accurate for the simultaneous determination of matrine and secnidazole without interference from the excipients in the suppository dosage form.

**DISCUSSION**

This study was essentially focused on the simultaneous determination of co-formulated matrine and secnidazole in suppositories. Following initial trials to establish optimum conditions, a mixture of acetonitrile–triethylamine (0.05%) in 0.025 mol/L KH2PO4 (20:80, v/v) was
selected as the optimum mobile phase for baseline separation and short retention time. Matrine and secnidazole were soluble in organic solvents including methanol and acetonitrile. The use of mobile phase as extraction reagent provided minimal impurities and better separation. The developed method is simple, rapid, cost-effective, highly sensitive and provides good reproducibility and accuracy for the simultaneous determination of matrine and secnidazole when co-formulated in suppositories.

**CONCLUSION**

The developed method is simple, rapid, cost-effective, highly sensitive and provides good reproducibility and accuracy for the simultaneous determination of matrine and secnidazole when co-formulated in suppositories.

**ACKNOWLEDGEMENT**

The authors would like to acknowledge the financial support provided by Xinxiang Medical University.

**REFERENCES**

1. Livengood CH. Bacterial vaginosis: an overview for 2009. Rev Obstet Gynecol 2009; 2: 28–37.
2. Donders GG, Calisteren KV, Bellien G, Reybrouck R, Van den Bosch T, Rijphagen I, Lierde SV. Predictive value for preterm birth of abnormal vaginal flora, bacterial vaginosis and aerobic vaginitis during the first trimester of pregnancy. Int J Obstet Gynaecol 2009; 116: 1315–1324.
3. Brotman RM, Klebanoff MA, Nansel TR, Yu KF, Andrews W, Zhao J, Schwebke J. R. Bacterial vaginosis assessed by gram stain and diminished colonization resistance to incident gonococcal, chlamydial, and trichomonal genital infection. J Infect Dis 2010; 202: 1907–1915.
4. Allsworth JE, Lewis VA, Peipert J.F. Viral sexually transmitted infections and bacterial vaginosis: 2001-2004 national health and nutrition examination survey data. Sex Transm Dis 2008; 35: 791–796.
5. Jokipii L, Jokipii AM. Comparative evaluation of the 2-methyl-5-nitroimidazole combineds dimetridazole, metronidazole, secnidazole, ornidazole, tindazole, camidazole, and panidazole against bacteroides fragilis and other bacteria of the bacteroides fragilis group. Antimicrob Agents Ch 1985; 28: 561-564.
6. Smart S, Singal A, Mindel A. Social and sexual risk factors for bacterial vaginosis. Sex Transm Infect 2004; 80: 58–62.
7. Gardner HL, Dukes CD. Haemophilus vaginalis vaginitis: a newly defined specific infection previously classified non-specific vaginitis. Am J Obstet Gynecol 1955; 69: 962–976.
8. Han XZh, Liu X, Nie J, Fu XT, Jin ShR, Yu W.M. The preparation of matrine sustained- release tablet and the determination of its dissolution rate. Chin Trad Med 2008; 30: 365-368.
9. Matrine. [cited 2011 July 8]. Available from: http://baike.baidu.com/view/140662.htm.
10. Xue AH, Zhu WJ. Survey studies on pharmacological effects of matrine, Tianjin pharmacy 2010; 22: 62-65.
11. Matrine[homepage on the Internet]. State Food and Drug Administration [cited 2011 Sep 16]. Available from: http://www.sda.gov.cn/bzzzmd/bk1.htm.
12. ZhouY, Wei YH, Liu HX, Zhang G.Q, Wu XA. Preparation and invito evaluation of ethosomal total alkaloids of sophora alopecuroides loadedbya transmembrane pH-gradient method. AAPS Pharm Sci Tech 2010; 11: 1350-1358.
13. Zhan BU, Li DX, Gao M. The modern Research Progress of Matrine. Information on Traditional Chinese Medicine 2009; 26: 23-25.
14. Sun HW, Wang FCh, Ai LF. Simultaneous determination of seven nitroimidazolyl esidues in meat by using HPLC-UV detection with solid-phase extraction. J Chromatogr B 2007; 857: 296-300
15. Li XY, Sun JG, Wang GJ, Zheng YT, Yan B, Xie HT, Gu Y, Ren HCh. Determination of secnidazole in human plasma by high-performance liquid chromatography with UV detection and its application to the

**Table 1: Method robustness test results for matrine and secnidazole**

| System suitability parameter | Analyte | Variation in acetonitrile content of mobile phase | Variation in rate (mL/min) | flow | Variation in column temperature (℃) |
|-----------------------------|---------|----------------------------------------|-------------------------|------|----------------------------------|
| RSD (%)                     | Matrine | 19 20 21                               | 0.2 0.1 0.2             | 0.2  | 0.3 0.1 0.2                      |
|                             | Secnidazole | 19 20 21                               | 0.2 0.1 0.3             | 0.2  | 0.3 0.1 0.2                      |

**Trop J Pharm Res, June 2013;12 (3): 417**
bioequivalence studies. Biomed Chromatogr 2007; 21: 304-309.
16. El Wallily AF, Abdine HH, Razak OA, Zamel S. Spectrophotometric and HPLC determination of secnidazole in pharmaceutical tablets. J Pharm Biomed Anal 2000; 22: 887-897.
17. Yang Z, Gao S, Yin TJ, Kulkarni KH, Teng Y, You M, Hu M. Biopharmaceutical and pharmacokinetic characterization of matrine as determined by a sensitive and robust UPLC-MS/MS method. J Pharm Biomed Anal 2010; 51: 1120-1127.
18. Zhang XL, Xu HR, Chen WL, Chu NN, Li XN, Liu GY, Yu C. Matrine determination and pharmacokinetics in human plasma using LC/MS/MS. J Chromatogr B 2009; 877:3253-3256.
19. Zheng H, Chen G, Shi L, Lou Z, Chen F, Hu J. Determination of oxymatrine and its metabolite matrine in rat blood and dermal microdialysates by high throughput liquid chromatography/tandem mass spectrometry. J Pharm Biomed Anal 2009; 49: 427-433.